NLS Pharmaceutics Ltd
NLSP
|
$0.125
-3.99%
3.64%
36K
|
(0.0% 1d) (-25.6% 1m) (-91.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-87.5% volume)
Earnings Calendar:
Market Cap: $ 4,053,612
https://nlspharma.com
Sec Filling | Patents | 4 employees
NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage pharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company’s lead product candidate, Quilience® is a proprietary controlled release formulation of mazindol (mazindol CR), and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, which was used for many yearsto treat patients diagnosed with narcolepsy in compassionate use programs. NLS completed a phase 2 study in the U.S. evaluating mazindol CR in adult subjects with ADHD. The study met all primary and secondary endpoints and was well-tolerated. Quilience® has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy.
treatment nervous system
add to watch list Paper trade email alert is off
Press-releases
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
Published: 2024-03-20 (Crawled : 13:00) - biospace.com/
NLSP | $0.125 -3.99% 3.64% 36K
|
|
| O: 7.65%
H: 31.03%
C: -45.86%
agonist license global platform
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
Published: 2024-03-14 (Crawled : 12:30) - biospace.com/
NLSP | $0.125 -3.99% 3.64% 36K
|
|
| O: 2.52%
H: 0.0%
C: -4.31%
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance
Published: 2024-03-11 (Crawled : 12:00) - biospace.com/
NLSP | $0.125 -3.99% 3.64% 36K
|
|
| O: 4.99%
H: 11.89%
C: 3.79%
nasdaq
NLS Pharmaceutics Announces Election of Additional Board Members
Published: 2023-11-28 (Crawled : 17:00) - biospace.com/
NLSP | $0.125 -3.99% 3.64% 36K
|
|
| O: 3.01%
H: 1.17%
C: -4.82%
NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia
Published: 2023-11-27 (Crawled : 14:30) - biospace.com/
NLSP | $0.125 -3.99% 3.64% 36K
|
|
| O: -0.02%
H: 7.47%
C: -2.9%
narcolepsy disorders
NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan
Published: 2023-11-16 (Crawled : 14:30) - biospace.com/
NLSP | $0.125 -3.99% 3.64% 36K
|
|
| O: -2.25%
H: 0.21%
C: -32.93%
NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol
Published: 2023-07-03 (Crawled : 14:00) - biospace.com/
NLSP | $0.125 -3.99% 3.64% 36K
|
|
| O: 13.64%
H: 11.2%
C: -4.0%
fda narcolepsy approval review treatment program study
NLS Pharmaceutics Company Update and Webcast Today Postponed
Published: 2023-06-30 (Crawled : 14:20) - biospace.com/
NLSP | $0.125 -3.99% 3.64% 36K
|
|
| O: 0.7%
H: 47.88%
C: 18.74%
update today
CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
Published: 2023-06-19 (Crawled : 13:00) - biospace.com/
NLSP | $0.125 -3.99% 3.64% 36K
|
| Email alert
Add to watchlist
conference group
NLS Pharmaceutics Announces Company Update Webcast
Published: 2023-06-19 (Crawled : 12:20) - biospace.com/
NLSP | $0.125 -3.99% 3.64% 36K
|
| Email alert
Add to watchlist
update
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 1.12% 1.5M
|
Finance
|
22:30
NWFL | News | $24.21 0.42% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.68 -0.73% 39.71% 20K
|
Utilities
|
20:01
MNSB P 310 | $15.89 -2.87% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.55 0.28% 0.28% 7.1K
|
Consumer Non-Durables
|
20:10